within Pharmacolibrary.Drugs.ATC.N;

model N04BX02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.35,
    Cl             = 650 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00795,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), used as an adjunct to levodopa/carbidopa therapy in the management of Parkinson's disease. It is approved and widely used today to prolong the effect of levodopa by blocking its peripheral degradation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adults after a single oral 200 mg dose.</p><h4>References</h4><ol><li><p>Rouru, J, Gordin, A, Huupponen, R, Huhtala, S, Savontaus, E, Korpela, K, Reinikainen, K, &amp; Scheinin, M (1999). Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. <i>European journal of clinical pharmacology</i> 55(6) 461–467. DOI:<a href=&quot;https://doi.org/10.1007/s002280050657&quot;>10.1007/s002280050657</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10492060/&quot;>https://pubmed.ncbi.nlm.nih.gov/10492060</a></p></li><li><p>Keränen, T, Gordin, A, Karlsson, M, Korpela, K, Pentikäinen, PJ, Rita, H, Schultz, E, Seppälä, L, &amp; Wikberg, T (1994). Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. <i>European journal of clinical pharmacology</i> 46(2) 151–157. DOI:<a href=&quot;https://doi.org/10.1007/BF00199880&quot;>10.1007/BF00199880</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8039535/&quot;>https://pubmed.ncbi.nlm.nih.gov/8039535</a></p></li><li><p>Miyaue, N, Ito, Y, Yamanishi, Y, Tada, S, Ando, R, Yabe, H, &amp; Nagai, M (2024). Optimization of oral entacapone administration in patients undergoing levodopa-carbidopa intestinal gel treatment. <i>Journal of the neurological sciences</i> 457 122901–None. DOI:<a href=&quot;https://doi.org/10.1016/j.jns.2024.122901&quot;>10.1016/j.jns.2024.122901</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38280299/&quot;>https://pubmed.ncbi.nlm.nih.gov/38280299</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N04BX02;
